Q2 EPS Estimates for Flora Growth Lowered by Roth Capital

Flora Growth Corp. (NASDAQ:FLGC) – Roth Capital lowered their Q2 2025 EPS estimates for Flora Growth in a research note issued on Friday, November 15th. Roth Capital analyst W. Kirk now forecasts that the company will post earnings per share of $0.02 for the quarter, down from their previous estimate of $0.07. The consensus estimate for Flora Growth’s current full-year earnings is ($0.48) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2025 earnings at $0.02 EPS and Q4 2025 earnings at $0.02 EPS.

Separately, Alliance Global Partners reaffirmed a “neutral” rating on shares of Flora Growth in a research report on Thursday, August 15th.

Flora Growth Trading Up 2.6 %

Shares of FLGC stock opened at $1.20 on Monday. Flora Growth has a 12 month low of $0.70 and a 12 month high of $2.93. The stock has a 50 day moving average of $1.46 and a two-hundred day moving average of $1.23. The company has a current ratio of 1.02, a quick ratio of 0.79 and a debt-to-equity ratio of 0.43.

Institutional Trading of Flora Growth

An institutional investor recently raised its position in Flora Growth stock. Renaissance Technologies LLC raised its stake in shares of Flora Growth Corp. (NASDAQ:FLGC) by 105.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 159,595 shares of the company’s stock after purchasing an additional 81,982 shares during the quarter. Renaissance Technologies LLC owned 1.19% of Flora Growth worth $163,000 as of its most recent filing with the Securities and Exchange Commission. 36.01% of the stock is owned by institutional investors.

About Flora Growth

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.